LOGIN  |  REGISTER
Cue Biopharma

Latest Medical Stock News

FILTER BY TOPIC:     Medical Devices   Diagnostics & Research   FDA 510(k) Clearance   Psychedelics        List of All Medical Stocks  

Quanterix to Present at Cowen’s 44th Annual Health Care Conference

February 23
Last Trade: 24.87 -0.64 -2.51

BILLERICA, Mass. / Feb 23, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 44th Annual Health Care Conference. Quanterix’s session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made available to attendees and, via webcast, the general...Read more


Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

February 23
Last Trade: 1.30 -0.56 -30.11

TORONTO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 817,748 shares of common stock at a purchase price of $1.465 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company...Read more


Waters to Present at the TD Cowen 44th Annual Health Care Conference

February 22
Last Trade: 331.25 0.70 0.21

MILFORD, Mass., Feb. 22, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Monday, March 4th, 2024 at 11:10AM Eastern Time A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website...Read more


Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)

February 22
Last Trade: 184.21 -12.93 -6.56

Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass. / Feb 22, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2023. Full Year Financial Highlights: Full year 2023 revenue of $1.7...Read more


Teleflex Reports Fourth Quarter and Full Year 2023 Financial Results

February 22
Last Trade: 237.75 0.05 0.02

WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2023. Fourth quarter financial summary Revenues of $773.9 million, reflective of five fewer shipping days year-over-year, up 2.1% compared to the prior year period; up 0.7% on a constant currency basis GAAP diluted EPS from continuing operations of...Read more


Penumbra Reports Fourth Quarter and Full Year 2023 Financial Results

February 22
Last Trade: 238.37 -24.31 -9.25

ALAMEDA, Calif., Feb. 22, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Revenue of $284.7 million for the fourth quarter of 2023, an increase of 28.7% or 27.9% in constant currency1 compared to the fourth quarter of 2022. Revenue of $1,058.5...Read more


Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results

February 22
Last Trade: 66.27 1.22 1.88

Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023 GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023 GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023 Adjusted fully diluted net income per share of $1.75 and $6.23 for the fourth quarter and full year 2023 Net cash provided by operating...Read more


iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results

February 22
Last Trade: 105.07 -10.00 -8.69

SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Grew fourth quarter 2023 patient registrations in excess of 22% compared to the fourth...Read more


Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

February 22
Last Trade: 19.42 -2.85 -12.80

Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million PALO ALTO, Calif. / Feb 22, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue of $155.1 million for...Read more


Twist Bioscience to Present at Upcoming Investor Conferences

February 22
Last Trade: 38.20 -0.42 -1.09

SOUTH SAN FRANCISCO, Calif. / Feb 22, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside...Read more


Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

February 22
Last Trade: 15.22 -0.02 -0.13

Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug Administration Enrollment completed in phase 3 TRIDENT trial studying the use of TTFields therapy and concomitant radiation for the treatment of newly diagnosed GBM ROOT, Switzerland / Feb 22, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today reported financial...Read more


AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

February 22
Last Trade: 17.10 0.09 0.53

VALENCIA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Commercial revenue increased approximately 50% to $14.1 million compared...Read more


Sanara MedTech Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023

February 22
Last Trade: 37.97 0.00 0.00

FORT WORTH, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today certain unaudited preliminary...Read more


RetinalGeniX Technologies Granted a Patent for System And Method For Visualization Of Ocular Anatomy

February 22
Last Trade: 3.50 0.00 0.00

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy. The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes. It is an...Read more


Owlet Announces Strong Preliminary Fourth Quarter 2023 Results and to Report Fourth Quarter 2023 Financial Results on March 7, 2024

February 22
Last Trade: 6.17 1.15 22.91

LEHI, Utah / Feb 22, 2024 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the following preliminary unaudited results for the fourth quarter 2023. Preliminary Unaudited Q4 2023 Financial Highlights Q4 Gross Sales is expected to be approximately $32.9 million, up 114% year over year. Q4 Net Revenue is expected to be approximately $21.0 million, up 75% year...Read more


Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference

February 22
Last Trade: 4.46 0.05 1.13

AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2,...Read more


Spectral AI Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024

February 22
Last Trade: 1.87 0.00 0.00

DALLAS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its predictive software DeepView AI®-Burn has obtained the final stage of UK Conformity Assessed (UKCA) authorization, for aiding in burn wound diagnosis in the United...Read more


Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies

February 22
Last Trade: 1.20 -0.07 -5.51

RA'ANANA, Israel, Feb. 22, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company targeting to supersede mechanical ventilators, has unveiled an exclusive in-house capability designed to simulate both the arterial and venous blood parameters of patients with specific medical conditions without the need of in vivo...Read more


ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

February 22
Last Trade: 0.53 0.01 2.78

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously...Read more


Venus Concept Announces CE Mark for Venus Versa Pro in Europe

February 22
Last Trade: 1.30 -0.56 -30.11

TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received the CE Mark from DEKRA Certification B.V. to market the Venus Versa Pro system in the European Union. This follows the Company’s announcement on November 1, 2023 regarding the commercial launch of the device in the United...Read more


ReShape Lifesciences Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

February 22
Last Trade: 0.15 -0.0054 -3.39

FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band® 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas, Fort...Read more


NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

February 22
Last Trade: 3.11 0.17 5.78

WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "Quell® Fibromyalgia growth accelerated in Q4 2023 reflecting the addition in Q3 2023 of two field business...Read more


Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry

February 22
Last Trade: 0.15 -0.0026 -1.71

Waterlase iPlus Premier Edition™ is being unveiled at the Chicago Midwinter Meeting 2024 LAKE FOREST, CA / ACCESSWIRE / February 22, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608. The...Read more


Tenon Medical Announces Issuance of Notice of Allowance of Patent Application Which Further Enhances Important Claims for its Sacroiliac Joint Implant

February 22
Last Trade: 1.03 -0.05 -4.63

Received Notice of Allowance from the USPTO on February 15, 2024 LOS GATOS, CA / ACCESSWIRE / February 22, 2024 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced that on February 15, 2024, the United States Patent and Trademark Office ("USPTO") issued a Notice of Allowance for U.S. Patent Application Serial Number...Read more


Motus GI Announces Exercise of Warrants for $2.7 Million Gross Proceeds

February 22
Last Trade: 0.82 0.03 3.86

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of...Read more


Becton Dickinson Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore

February 21
Last Trade: 246.20 2.58 1.06

First-Ever Program in the Country to Offer At-Home Self-Collection of Samples for HPV Testing SINGAPORE, Feb. 21, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in...Read more


IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024

February 21
Last Trade: 247.26 -0.07 -0.03

RESEARCH TRIANGLE PARK, N.C. / Feb 21, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at...Read more


ICON Reports Fourth Quarter and Full Year 2023 Results

February 21
Last Trade: 314.19 0.82 0.26

Highlights Net business wins in the quarter of $2,531 million; a net book to bill of 1.22. Full year net business wins of $9,946 million; a net book to bill of 1.22. Closing backlog of $22.8 billion, an increase of 2.4% on quarter three 2023 and an increase of 10.0% on quarter four 2022. Quarter four revenue of $2,066.2 million representing an increase of 5.3% on prior year revenue. Full year revenue of $8,120.2 million representing a...Read more


Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery

February 21
Last Trade: 127.08 1.74 1.39

Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health Impacting Care BIRMINGHAM, Ala. and SAN FRANCISCO, Feb. 21, 2024 /PRNewswire/ -- Pack Health, a Quest Diagnostics (NYSE: DGX) company specializing in patient engagement, and Instacart (NASDAQ: CART), the leading grocery technology...Read more


Revvity to Present at Upcoming Investor Conferences

February 21
Last Trade: 104.44 0.07 0.07

WALTHAM, Mass. / Feb 21, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sciences Access Day - New York City, NY Thursday, February 29, 2024 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 44th Annual Health Care Conference – Boston, MA Monday, March 4, 2024...Read more


Charles River Laboratories and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing

February 21
Last Trade: 247.71 0.81 0.33

WILMINGTON, Mass. & OKLAHOMA CITY / Feb 21, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC® (Chemistry, Manufacturing and Controls) platform. This...Read more


Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

February 21
Last Trade: 196.52 3.12 1.61

Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended...Read more


Exact Sciences Announces Fourth Quarter 2023 Results

February 21
Last Trade: 57.53 -1.96 -3.29

Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quarter and 2023 highlights Total fourth quarter revenue of $647 million, an increase of 17%, or 18% on a core revenue basis, with Screening revenue of $487 million and Precision Oncology revenue of $160 million Total 2023 revenue of $2.50 billion, an increase of 20%, or 24% on a core revenue basis, with Screening revenue of...Read more


Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

February 21
Last Trade: 17.60 0.28 1.62

Fourth-Quarter 2023 Financial Results Revenue of $1.173 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $54 Million Adjusted EBITDA (non-GAAP)1 of $231 Million Revenue Grew 18% as Reported and 19% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2022, Driven by Growth Across All Segments Full-Year 2023 Financial Results Revenue of $4.146 Billion GAAP Net Loss Attributable to Bausch + Lomb...Read more


Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

February 21
Last Trade: 89.57 -1.89 -2.07

ALISO VIEJO, Calif. / Feb 21, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: Record net sales of $82.4 million in Q4 2023 increased 16% year-over-year on...Read more


Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference

February 21
Last Trade: 73.51 -1.39 -1.86

BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5, 2024 at 7:30 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following...Read more


Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day

February 21
Last Trade: 73.51 -1.39 -1.86

BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following...Read more


QuidelOrtho Announces Changes in Executive Leadership

February 21
Last Trade: 46.89 0.34 0.73

The Board of Directors has terminated President and Chief Executive Officer, Douglas Bryant and appointed, on an interim basis, Michael Iskra as Chief Executive Officer and Robert Bujarski as President SAN DIEGO / Feb 21, 2024 / Business Wire / The Board of Directors (the “Board”) of QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”) has made significant decisions aimed to enhance operational efficiency, drive...Read more


LivaNova Reports Fourth-Quarter and Full-Year 2023 Results

February 21
Last Trade: 57.12 0.88 1.56

LONDON / Feb 21, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights1 Fourth-quarter revenue of $310.1 million increased 12.8 percent on a reported basis and 11.9 percent on a constant-currency basis, as compared to the prior-year period Fourth-quarter...Read more


Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance

February 21
Last Trade: 29.13 4.13 16.52

SAN DIEGO / Feb 21, 2024 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2023 and provided its financial guidance for the year ending December 31, 2024. Fourth Quarter and Recent Highlights Worldwide installed base increased 7 percent to approximately 452,000 in-warranty customers...Read more


Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

February 21
Last Trade: 15.30 -1.21 -7.33

Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results. The company also provided first-quarter and full-year 2024 financial guidance. "Our fourth quarter performance...Read more


CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

February 21
Last Trade: 8.27 0.00 0.00

BRISBANE, Calif. / Feb 21, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular...Read more


Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results

February 21
Last Trade: 10.81 -1.05 -8.85

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2023 ended December 31, 2023. Recent Highlights Delivered $68.7 million in worldwide revenue for the full year of 2023, a 28% increase over the prior year Achieved record...Read more


Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

February 21
Last Trade: 10.81 -1.05 -8.85

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company’s President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as...Read more


Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results

February 21
Last Trade: 3.72 0.31 9.09

SAN JOSE, Calif. / Feb 21, 2024 / Business Wire / Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter, Year-End Results, and Recent Highlights Recorded net revenue of $30.5 million in the fourth...Read more


ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

February 21
Last Trade: 7.27 -0.22 -2.94

SOLANA BEACH, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced FDA Clearance and first-in-human cases using the ClearPoint 2.2 Software with integrated Maestro Brain Modeling, and also the publication of a key validation study for its ClearPoint Maestro® Brain Model in...Read more


MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6

February 21
Last Trade: 3.57 -0.03 -0.83

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 21, 2024 – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended...Read more


Apyx Medical Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting

February 21
Last Trade: 2.01 -0.13 -6.07

Presentation hosted by Dr. Michael Kluska to feature the results of a retrospective clinical study comparing the use of Renuvion to a competing technology when used in conjunction with liposuction or body contouring, demonstrating significantly fewer adverse events CLEARWATER, Fla. / Feb 21, 2024 / Business Wire / Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma...Read more


Hyperfine Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes

February 21
Last Trade: 1.03 0.00 0.00

The collaboration kicked off at the 2024 All-Star game in Indianapolis Athletic Heart will use the Swoop® Portable MR Imaging® system to provide brain imaging GUILFORD, Conn. & ORLANDO, Fla. / Feb 21, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system–the Swoop®...Read more


DarioHealth acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions

February 21
Last Trade: 2.03 0.005 0.25

Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the acquisition Dario prices $22.4 million equity financing Company to host conference call today at 8:30am ET. Dial-in and replay information below NEW YORK, Feb. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the...Read more


Modular Medical Announces Closing of $10 Million Public Offering

February 21
Last Trade: 1.78 0.03 1.71

SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, announced today the closing of its previously announced underwritten public offering (the "offering") of 9,090,910 shares of its common stock, led by Manchester Explorer,...Read more


Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

February 21
Last Trade: 1.29 0.14 12.50

IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, “LabCorp” (NYSE: LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica,...Read more


Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

February 21
Last Trade: 0.94 -0.02 -1.71

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy. TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan. The partnership...Read more


NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders

February 21
Last Trade: 2.35 0.03 1.08

LANGHORNE, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 462,090 of its shares of common stock and the issuance of warrants to...Read more


Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024

February 21
Last Trade: 1.05 -0.05 -4.55

Topline growth with better quality revenue mix Increase in subscription revenue (fixed) vs usage based revenue (variable), reducing seasonality impact with more predictable revenue Improved margins Lower costs with improved selling expense Stronger path to breakeven REDWOOD CITY, CA / ACCESSWIRE / February 21, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating...Read more


Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia

February 21
Last Trade: 0.35 -0.01 -3.05

NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is preparing to make the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders have been placed through a collaborative effort between...Read more


Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices

February 21
Last Trade: 1.70 -0.0066 -0.39

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a...Read more


Tenon Medical Raises Approximately $2.6 Million in Series A Preferred Stock

February 21
Last Trade: 1.03 -0.05 -4.63

Raises Approximately $2.6 Million in Gross Proceeds  Retires $1.25 Million in Secured Debt  LOS GATOS, CA / ACCESSWIRE / February 21, 2024 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced the closing of a private placement of 172,239 shares of the Company's Series A Preferred Stock (the "Preferred...Read more


Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

February 21
Last Trade: 1.24 -0.03 -2.36

SAN FRANCISCO / Feb 21, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed. VNS is a growing market that is part of the $8.3B global neurostimulation market, which has a projected CAGR of...Read more


Motus GI Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

February 21
Last Trade: 0.82 0.03 3.86

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.” “We are pleased to announce further...Read more


Medtronic reports third quarter fiscal 2024 financial results

February 20
Last Trade: 85.67 0.61 0.72

Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance DUBLIN, Feb. 20, 2024 /CNW/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024. Key...Read more


IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

February 20
Last Trade: 576.29 4.98 0.87

WESTBROOK, Maine / Feb 20, 2024 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the...Read more


Charles River Laboratories Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

February 20
Last Trade: 247.71 0.81 0.33

The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. WILMINGTON, Mass. / Feb 20, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The...Read more


Teleflex to Present at the 45th Annual Raymond James Institutional Investors Conference

February 20
Last Trade: 237.75 0.05 0.02

WAYNE, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 5, 2024, at 1:40 p.m. (ET). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the...Read more


Masimo and UCHealth Announce a Clinical Monitoring Partnership to Improve Care with Telehealth

February 20
Last Trade: 132.21 1.20 0.92

IRVINE, Calif. & DENVER / Feb 20, 2024 / Business Wire / Masimo (NASDAQ: MASI), a leading global provider of medical technology and automation solutions, and UCHealth, a nationally recognized network of hospitals, clinics, and providers based in Colorado, announced today that they are entering into a strategic collaboration to improve the standard of patient care using the latest in virtual care and telehealth capabilities. With an...Read more


Globus Medical Reports Fourth Quarter and Full Year 2023 Results

February 20
Last Trade: 56.29 1.03 1.86

AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Fourth Quarter 2023: Worldwide net sales were $616.5 million, an increase of 124.6%, or 123.8% on a constant currency basis GAAP net income for the quarter was $15.0 million GAAP diluted earnings per share...Read more


NeoGenomics Reports Fourth Quarter and Full Year 2023 Results

February 20
Last Trade: 16.79 0.34 2.07

Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million FORT MYERS, Fla. / Feb 20, 2024 / Business Wire / NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights Fourth quarter consolidated revenue increased...Read more


Owens & Minor Reports Fourth Quarter and Full Year 2023 Financial Results

February 20
Last Trade: 23.88 0.68 2.93

Business Delivered Strong Operating Margin Improvement in Fourth Quarter Robust Full Year Operating Cash Flow Generation Enabled Significant Debt Reduction RICHMOND, Va. / Feb 20, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the fourth quarter and year ended December 31, 2023. Full Year 2023 Key Highlights: Consolidated revenue of $10.3 billion Delivered $741 million of operating...Read more


MiMedx to Present at TD Cowen 44th Annual Health Care Conference

February 20
Last Trade: 8.20 0.02 0.24

MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference. TD Cowen | Boston, MA | March 4-6, 2024Presentation: Monday, March 4, 2024 at 2:10 PM ETWebcast: Click here to access Institutional investors interested in meeting with senior management may contact their TD Cowen...Read more


Avanos Medical Announces Fourth Quarter and Full-Year 2023 Results

February 20
Last Trade: 19.69 0.10 0.51

ALPHARETTA, Ga., Feb. 20, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2023 results. "We were very pleased with the overall execution on our transformation initiative last year, which sets the foundation for more profitable growth in 2024 and for reaching our mid-term financial targets in 2025," said Joe Woody, Avanos's chief executive officer. Woody continued, "We believe we are...Read more


Tactile Systems Technology Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Outlook

February 20
Last Trade: 15.84 1.71 12.10

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights: Total revenue increased 5% over prior year to $77.7 million Net income increased 77% over prior...Read more


Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024

February 20
Last Trade: 5.85 0.31 5.60

IRVINE, CA / ACCESSWIRE / February 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 American Venous Forum (AVF) Annual Meeting being held March 3-6, 2024 in Tampa, Florida. The presentation will be made on Wednesday,...Read more


Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Research Examining the High Rates of Re-Operations Following Breast-Conserving Surgeries and the Associated Increased Healthcare Costs

February 20
Last Trade: 0.99 -0.01 -1.00

DALLAS and TORONTO, Feb. 20, 2024 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced results from a new study1 published in the Annals of Surgical Oncology that provide a comprehensive and up-to-date understanding of population-level reoperation rates and incremental healthcare costs associated with...Read more


Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® to Maine Dental Group, a Premier Group Practice with 21 Locations Across the Northeast

February 20
Last Trade: 0.69 0.01 1.94

ROSELAND, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced sales of its STA Single Tooth Anesthesia System® (STA) with Maine Dental Group, a premier group of 21 dental practices across the northeastern United States. Arjan Haverhals, Chief Executive Officer of Milestone...Read more


VentriPoint Diagnostics Successfully Showcases A.I.-Powered Heart-Scanning Technology at Prestigious International Cardiology Conferences

February 20
Last Trade: 0.29 0.005 1.79

Hamburg, Germany — TheNewswire --- February 20, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is delighted to report its participation at the 53rd annual meeting of the German Society for Thoracic, Heart and Vascular Surgery. The event, held Feb. 19, was held in conjunction with the annual meeting of the German Society for Paediatric Cardiology and Congenital Heart Defects in Hamburg,...Read more


Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

February 20
Last Trade: 0.61 0.01 1.83

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its planned activities at the upcoming Technology and Heart Failure Therapeutics conference (THT 2024), which is produced by the Cardiovascular Research Foundation (CRF), taking place March 4-6, in Boston. Nuwellis will exhibit at booth #8, host a...Read more


Henry Schein Presents Comprehensive Lineup of Solutions at the 2024 Chicago Dental Society Midwinter Meeting

February 19
Last Trade: 79.86 2.78 3.61

Company's Holistic Approach to Elevating the Customer Experience on Display MELVILLE, N.Y. / Feb 19, 2024 / Business Wire / Henry Schein, Inc. (Nasdaq: HSIC) today announced it will present at the 2024 Chicago Dental Society Midwinter Meeting a comprehensive lineup of digital equipment, technology solutions, and business services designed to help dental practices operate more efficiently and effectively. The Midwinter Meeting, which...Read more


Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

February 16
Last Trade: 0.35 -0.01 -3.05

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS) (NASDAQ: STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics...Read more


Becton Dickinson to Present at Investor Healthcare Conferences

February 15
Last Trade: 246.20 2.58 1.06

FRANKLIN LAKES, N.J., Feb. 15, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: Citi's 2024 Unplugged Medtech and Life Sciences Access DayFebruary 29, 20248:00 am Eastern Time Barclays 26th Annual Global Healthcare ConferenceMarch 13, 20249:30 am Eastern Time The live webcasts of BD's...Read more


IDEXX Laboratories Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

February 15
Last Trade: 576.29 4.98 0.87

Initial Vello Users Show an Average 19% Reduction in No-Show Rate, Enabling More Clinical Visits WESTBROOK, Maine, Feb. 15, 2024 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of Vello, a software solution that seamlessly connects veterinary practices and clients through modern, digital tools. As the only pet owner engagement solution purpose-built for IDEXX...Read more


West Pharmaceutical Announces Fourth-Quarter and Full-Year 2023 Results

February 15
Last Trade: 367.44 7.54 2.10

Conference Call Scheduled for 9 a.m. EST Today  EXTON, Pa., Feb. 15, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth...Read more


Labcorp Announces 2023 Fourth Quarter and Full Year Results

February 15
Last Trade: 219.16 1.39 0.64

Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year: Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs $11.86 billion Diluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94 Adjusted EPS: Q4 of $3.30 vs $3.05 ; Full year of $13.56 vs $16.66 Free Cash Flow: Q4 of $414.2 million vs $508.1 million; Full year of $748.7 million...Read more


Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results

February 15
Last Trade: 260.83 -9.70 -3.59

SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full...Read more


Bio-Rad Laboratories Reports Fourth-Quarter and Full-Year 2023 Financial Results

February 15
Last Trade: 337.99 -0.48 -0.14

HERCULES, Calif. / Feb 15, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681.2 million, a decrease of 6.7 percent compared to $730.3 million reported for the fourth quarter of 2022. On a...Read more


Merit Medical Systems Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

February 15
Last Trade: 79.81 0.01 0.01

SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the SCOUT® MD™ Surgical Guidance System. The release of the new guidance system demonstrates Merit’s ongoing leadership in oncology and marks a significant advancement in breast cancer care. SCOUT MD broadens Merit’s oncology...Read more


Integer Reports Results for Fourth Quarter and Full Year 2023

February 15
Last Trade: 102.00 1.82 1.82

Strong 4Q and Full Year sales and profit increase versus last year Expect 9% to 11% sales growth in 2024 with expanding margins  PLANO, Texas, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three and twelve months ended December 31, 2023. Unless otherwise stated, all results and comparisons are from continuing...Read more


Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

February 15
Last Trade: 22.72 -0.38 -1.65

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she...Read more


AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results

February 15
Last Trade: 33.56 -0.44 -1.29

Fourth Quarter 2023 Worldwide revenue of $106.5 million – an increase of 21.0% year over year Full Year 2023 Worldwide revenue of $399.2 million – an increase of 20.8% year over year Full Year 2023 U.S. revenue of $333.5 million – an increase of 20.3% year over year Full Year 2023 International revenue of $65.7 million – an increase of 23.5% year over year Full Year 2023 Net loss of $30.4 million – an improvement of $16.0 million year...Read more


PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results

February 15
Last Trade: 5.11 -0.02 -0.39

MENLO PARK, Calif., Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023. Fourth quarter results Revenue of $58.4 million, a 113% increase compared with $27.4 million in the prior-year period. Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period. Consumables revenue of $18.9 million compared with...Read more


Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

February 15
Last Trade: 20.27 0.56 2.84

Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis Achieved revenue of $354.0 million for the full year of 2023 versus $313.8 million for the full year of 2022, an increase of 13% on a GAAP basis and 12% on a non-GAAP constant currency...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Today's Medical Gainers

 
CompanyChangeLast Trade
Mettler-Toledo 17.01 1.43 $1,209.79
Atrion 10.15 2.98 $350.32
Medpace 7.98 2.03 $401.67
West Pharmaceutical 7.54 2.10 $367.44
McKesson 5.94 1.16 $516.24
IDEXX Laboratories 4.98 0.87 $576.29
Thermo Fisher Scientific 4.22 0.75 $564.71
Tandem Diabetes Care 4.13 16.52 $29.13
Repligen 3.12 1.61 $196.52
Henry Schein 2.78 3.61 $79.86
Becton Dickinson 2.58 1.06 $246.20
Trinity Biotech 1.95 435.95 $2.40
Stryker 1.88 0.53 $355.03
Integer 1.82 1.82 $102.00
Quest Diagnostics 1.74 1.39 $127.08
Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE
List of Medical Stocks

Medical Stocks

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB